FDC Ltd Q1 FY27 Results

FDC Limited's net profit rose 9.2% year-on-year to Rs 132 crore in the first quarter of fiscal year 2027. Revenue from operations grew 3.0% to Rs 668 crore.

Reader Takeaway: International business surges while domestic segment faces pressure; US FDA approval offers future growth.

What just happened

FDC Ltd announced its financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a 3.0% year-on-year increase in Revenue from Operations to Rs 668 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a modest rise of 1.9% to Rs 143 crore. Profit After Tax (PAT) grew by a healthier 9.2% to Rs 132 crore, translating to an Earnings Per Share (EPS) of Rs 8.14, up from Rs 7.45 in the previous year's corresponding quarter.

Why this matters

The results showcase a bifurcated performance. While the international business, particularly in the US, is booming, the crucial domestic formulations segment is experiencing a slowdown. The US FDA approval for Cefixime for Oral Suspension is a significant strategic win, boosting the outlook for the US market, which has been a strong growth driver for the company.

The backstory

FDC Ltd is a pharmaceutical company with a presence in both domestic and international markets, manufacturing a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished formulations. The company has been focusing on expanding its international footprint, especially in regulated markets like the US.

What changes now

The US FDA approval for Cefixime positions FDC to further capitalize on the US market. However, the company needs to address the underperformance in its domestic formulations segment, which constitutes about 85% of its total sales. Management's efforts to revive key domestic brands like Zifi, Enerzal, and Simyl MCT will be crucial.

Risks to watch

The primary risk lies in the sustained underperformance of the domestic formulations segment. A continued decline in this major revenue contributor could offset gains from international operations. Any slowdown in the international markets or regulatory challenges in key geographies also pose risks.

Peer comparison

(No specific peer comparison data available in the filing).

Context metrics (time-bound)

• Revenue: Rs 668 crore (Q1 FY27) vs Rs 648 crore (Q1 FY26) - up 3.0% YoY.
• PAT: Rs 132 crore (Q1 FY27) vs Rs 121 crore (Q1 FY26) - up 9.2% YoY.
• EBITDA Margin: 21.4% (Q1 FY27) vs 21.6% (Q1 FY26) - slight contraction.
• US International Formulations: Rs 34 crore (Q1 FY27) vs Rs 15.5 crore (Q1 FY26) - up 118.4% YoY.
• Domestic Formulations: Rs 569 crore (Q1 FY27) vs Rs 580 crore (Q1 FY26) - down 1.9% YoY.

What to track next

Investors will be closely watching the company's strategy to improve performance in the domestic market and the actual sales impact of the new US FDA-approved product. Continued growth in international markets and margin stability will also be key performance indicators.